drugset / Trial / NCT05108038

A Study to Evaluate the PK, PD and Safety of CKD-382 in Healthy Subjects

NCT05108038

Phase 1 Unknown 42 enrolled Chong Kun Dang Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

to evaluate the pharmacokinetics, pharmacodynamics and safety after single/multiple administration of CKD-382, D860 and D027 in healthy subjects

Timeline

Start
2021-10-07
Primary completion
2022-02
Completion
2022-02

Drugs

EvaluationDrugModalityDoseRoute
Subject CKD-382 Unknown
Subject D027 Unknown
Subject D860 Unknown